Trillium Therapeutics Inc.
DelistedCIK 1616212fmd_185TJNVK6AZADAHS8K35CEAWTGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2021, 11 periods
| Line item | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
| Total revenues | 0 | 0 | 0 |
| Research and development | 34 | 27 | 25 |
| Selling, general and administrative | 3 | 5 | – |
| Total operating expenses | – | 32 | 62 |
| Operating income | (36) | (32) | (61) |
| Interest expense | 0 | 0 | – |
| Interest and investment income | – | 1 | 2 |
| Other non-operating income (expense) | – | (6) | 2 |
| Income before taxes | (33) | (38) | (59) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (33) | (38) | (59) |
| Net income | (33) | (38) | (59) |